Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater efficacy with a lower ...
The EU has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, keeping the company a step ahead of arch rival Eli Lilly. Astellas Pharma US president Percival Barretto-Ko talks ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The world uses a lot of copper, but thanks to the energy transition and data centers, it’ll need a lot more. Between now and 2050, we’ll have to produce more copper than has been mined throughout all ...
LOS ANGELES, June 30, 2026 (GLOBE NEWSWIRE) — Arcturus, an advanced materials company that infuses carbon nanomaterials into metals to unlock step-change improvements in electrical, thermal, and ...
When organizers of the 1933 World’s Fair in Chicago wanted a splashy and futuristic way to kick things off on opening night, astronomer Edwin Frost of Yerkes Observatory had an idea: Turn on the ...
The last time I spoke about Arcturus Therapeutics Holdings Inc. (ARCT) it was with a Seeking Alpha article entitled "Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data." Regarding ...
In the preceding three months, 4 analysts have released ratings for Arcturus Therapeutics (NASDAQ:ARCT), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll ...
The company expects to initiate the 12-week Phase II ARCT-032 study in the first half of 2026, enrolling up to 20 participants and focusing on safety and early signs of clinical benefit. For ARCT-810, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market open, ...
Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results